[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568646":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":25,"locations":35,"responsibleParty":247,"collaborators":249,"id":252,"slug":10,"hasResults":253,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":253,"sex":258,"minAge":259,"maxAge":10,"enrollmentInfo":260,"targetDuration":10,"studyType":263,"phases":10,"briefSummary":264,"conditions":265,"keywords":268,"overallStatus":272,"whyStopped":10,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":282},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients",null,"Adult patients at very high risk of severe SARS-CoV-2 disease, hospitalized for SARS-CoV-2 infection from June 2023 to April 2024.",[13],"Other: Collection of data from the patient's medical file",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"Collection of data from the patient's medical file",[9],[19,22],{"name":20,"affiliation":5,"role":21},"Cléa Melenotte, M.D.","PRINCIPAL_INVESTIGATOR",{"name":23,"affiliation":5,"role":24},"Clémentine de La Porte, M.D.","STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Cléa Dr Melenotte, M.D.","CONTACT","33142192826","clea.melenotte@aphp.fr",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Hélène Morel","33171196346","helene.morel@aphp.fr",[36,51,64,77,93,106,119,132,145,161,169,179,192,205,218,231],{"facility":37,"status":10,"city":38,"state":10,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"CHU Angers","Angers","49000","France",{"type":42,"coordinates":43},"Point",[44,45],-0.55202,47.47156,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":10,"phoneExt":10,"email":50},"Vincent Dubée, M.D., PhD","vincent.dubee@chu-angers.fr",{"facility":52,"status":10,"city":53,"state":10,"zip":54,"country":40,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"CHU Caen","Caen","14000",{"type":42,"coordinates":56},[57,58],-0.35912,49.18585,{"lat":58,"lon":57},[61],{"name":62,"role":28,"phone":10,"phoneExt":10,"email":63},"Frédéric Rivière, M.D.","riviere-f@chu-caen.fr",{"facility":65,"status":10,"city":66,"state":10,"zip":67,"country":40,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Hôpital Pasteur, Colmar","Colmar","68000",{"type":42,"coordinates":69},[70,71],7.35584,48.08078,{"lat":71,"lon":70},[74],{"name":75,"role":28,"phone":10,"phoneExt":10,"email":76},"Martin Martinot, M.D.","martin.martinot@ch-colmar.fr",{"facility":78,"status":10,"city":79,"state":10,"zip":80,"country":40,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"CHD Vendée (La Roche sur Yon)","La Roche-sur-Yon","85000",{"type":42,"coordinates":82},[83,84],-1.42757,46.66974,{"lat":84,"lon":83},[87,90],{"name":88,"role":28,"phone":10,"phoneExt":10,"email":89},"Sophie Leautez-Nainville, M.D.","sophie.leautez@ght85.fr",{"name":91,"role":28,"phone":10,"phoneExt":10,"email":92},"Thomas Guimard, M.D.","thomas.guimard@ght85.fr",{"facility":94,"status":10,"city":95,"state":10,"zip":96,"country":40,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"CHRU Lille","Lille","59000",{"type":42,"coordinates":98},[99,100],3.05512,50.63391,{"lat":100,"lon":99},[103],{"name":104,"role":28,"phone":10,"phoneExt":10,"email":105},"Emmanuel Faure, M.D., PhD","emmanuel.faure2@chu-lille.fr",{"facility":107,"status":10,"city":108,"state":10,"zip":109,"country":40,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"CHU Nord Marseille","Marseille","13000",{"type":42,"coordinates":111},[112,113],5.38107,43.29695,{"lat":113,"lon":112},[116],{"name":117,"role":28,"phone":10,"phoneExt":10,"email":118},"Carole Eldin, M.D.","carole.eldin@ap-hm.fr",{"facility":120,"status":10,"city":121,"state":10,"zip":122,"country":40,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"CHU Nantes","Nantes","44000",{"type":42,"coordinates":124},[125,126],-1.55336,47.21725,{"lat":126,"lon":125},[129],{"name":130,"role":28,"phone":10,"phoneExt":10,"email":131},"Benjamin Gaborit, M.D.","benjamin.gaborit@chu-nantes.fr",{"facility":133,"status":10,"city":134,"state":10,"zip":135,"country":40,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"CHU Nîmes Caremeau","Nîmes","30000",{"type":42,"coordinates":137},[138,139],4.35788,43.83665,{"lat":139,"lon":138},[142],{"name":143,"role":28,"phone":10,"phoneExt":10,"email":144},"Paul Loubet, M.D.","Paul.loubet@chu-nimes.fr",{"facility":146,"status":10,"city":147,"state":10,"zip":148,"country":40,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Hôpital Saint-Louis","Paris","75010",{"type":42,"coordinates":150},[151,152],2.3488,48.85341,{"lat":152,"lon":151},[155,158],{"name":156,"role":28,"phone":10,"phoneExt":10,"email":157},"Laura Levi, M.D.","laura.levi@aphp.fr",{"name":159,"role":28,"phone":10,"phoneExt":10,"email":160},"Blandine Denis, M.D.","blandine.denis@aphp.fr",{"facility":162,"status":10,"city":147,"state":10,"zip":163,"country":40,"cosmosGeoPoint":164,"geoPoint":166,"contacts":167},"Hôpital Necker-Enfants Malades","75015",{"type":42,"coordinates":165},[151,152],{"lat":152,"lon":151},[168],{"name":20,"role":28,"phone":29,"phoneExt":10,"email":30},{"facility":170,"status":10,"city":147,"state":10,"zip":171,"country":40,"cosmosGeoPoint":172,"geoPoint":174,"contacts":175},"Hôpital Bichat","75018",{"type":42,"coordinates":173},[151,152],{"lat":152,"lon":151},[176],{"name":177,"role":28,"phone":10,"phoneExt":10,"email":178},"Nathan Peiffer-Smadja, M.D.","nathan.peiffer-smadja@aphp.fr",{"facility":180,"status":10,"city":181,"state":10,"zip":182,"country":40,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"CH Périgueux","Périgueux","24000",{"type":42,"coordinates":184},[185,186],0.71439,45.18691,{"lat":186,"lon":185},[189],{"name":190,"role":28,"phone":10,"phoneExt":10,"email":191},"Claire Aguilar, M.D.","claire.aguilar@ch-perigueux.fr",{"facility":193,"status":10,"city":194,"state":10,"zip":195,"country":40,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"CHU Poitiers","Poitiers","86000",{"type":42,"coordinates":197},[198,199],0.34348,46.58261,{"lat":199,"lon":198},[202],{"name":203,"role":28,"phone":10,"phoneExt":10,"email":204},"Gwenaël Le Moal, M.D., PhD","gwenael.le-moal@chu-poitiers.fr",{"facility":206,"status":10,"city":207,"state":10,"zip":208,"country":40,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"CHU Reims","Reims","51100",{"type":42,"coordinates":210},[211,212],4.02853,49.26526,{"lat":212,"lon":211},[215],{"name":216,"role":28,"phone":10,"phoneExt":10,"email":217},"Maxime Hentzien, M.D.","mhentzien@chu-reims.fr",{"facility":219,"status":10,"city":220,"state":10,"zip":221,"country":40,"cosmosGeoPoint":222,"geoPoint":226,"contacts":227},"CHU Sud Réunion","Saint-Pierre","97410",{"type":42,"coordinates":223},[224,225],5.40682,43.29282,{"lat":225,"lon":224},[228],{"name":229,"role":28,"phone":10,"phoneExt":10,"email":230},"Kevin Diallo, M.D.","kevin.diallo@chu-reunion.fr",{"facility":232,"status":10,"city":233,"state":10,"zip":234,"country":40,"cosmosGeoPoint":235,"geoPoint":239,"contacts":240},"CHU Toulouse","Toulouse","31000",{"type":42,"coordinates":236},[237,238],1.44367,43.60426,{"lat":238,"lon":237},[241,244],{"name":242,"role":28,"phone":10,"phoneExt":10,"email":243},"Guillaume Martin-Blondel, M.D.","martin-blondel.g@chu-toulouse.fr",{"name":245,"role":28,"phone":10,"phoneExt":10,"email":246},"Adrien Chan Sui Ko, M.D.","chansuiko.a@chu-toulouse.fr",{"type":248,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[250],{"name":251,"class":6},"URC-CIC Paris Descartes Necker Cochin","100568646",false,"NCT06683937","Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024","COV-ID","Inclusion Criteria:\n\n* Adult patients with SARS-CoV-2 in France, treated in a center participating in the study\n* Symptomatic patients for Covid-19 who have received mono- or dual therapy with nirmatrelvir\u002Fritonavir or remdesivir\n* SARS-CoV-2 positive by PCR on nasopharyngeal swab, ECBC or bronchoalveolar fluid\n* Hospitalization in a ward or day hospital for SARS-CoV-2 infection\n* Patients at very high risk of severe form of SARS-CoV-2\n\n  * Aggressive lymphomas (all types)\n  * Acute lymphocytic leukemia\n  * Acute myeloid leukemia\n  * Acute promyelocytic leukemia\n  * T-cell prolymphocytic leukemia\n  * Primary lymphoma of the central nervous system\n  * Stem cell transplant\n  * Light chain amyloidosis\n  * Chronic lymphocytic leukemia\n  * Multiple myeloma\n  * Hematopoietic stem cell transplant\n  * Solid organ transplant\n  * Being on the waiting list for an organ transplant\n  * Primary immunodeficiency;\n  * HIV patients with CD4 \\\u003C200\u002Fmm3 or with a detectable viral load\n  * Lymphopenia \\\u003C200\u002Fmm3\n  * Neutropenia \\\u003C1000\u002Fmm3 for \\> 1 week\n  * Patients receiving long-term immunosuppressive treatment (period of at least 3 months during treatment during infection) with:\n* anti-CD20 antibodies\n* anti-JAK\n* BTK inhibitors\n* azathioprine\n* cyclophosphamide\n* methotrexate\n* mycophenolate mofetil\n* CAR-T cell gene therapy\n* bi-phenotypic therapeutic antibodies\n* tacrolimus\n* sirolimus\n* long-term corticosteroids (prednisone equivalent dose \\>5mg for 3 months)\n\nExclusion Criteria:\n\n* Opposition formulated (following receipt of the study information note)\n* Patients who received convalescent plasma as first-line treatment for SARS-CoV-2 infection","ALL","18 Years",{"count":261,"type":262},300,"ESTIMATED","OBSERVATIONAL","Due to the lower virulence of circulating Omicron variants and the high seroprevalence of anti-SARS-CoV-2 antibodies, the incidence of cases and deaths related to the SARS-CoV-2 virus has significantly decreased in recent months worldwide. However, these infections remain a major public health problem in severely immunocompromised patients, who have decreased vaccine efficacy and are at higher risk of persistent SARS-CoV-2 viral shedding, relapses, secondary invasive fungal infection, intensive care unit hospitalization, and death than non-immunocompromised patients.\n\nThe research concerns adult patients at very high risk of severe SARS-CoV-2 disease, suffering from SARS-CoV-2 having resulted in hospitalization in a center participating in the study in France between June 1, 2023 and April 1, 2024 and having received mono- or dual therapy with nirmatrelvir\u002Fritonavir or remdesivir in order to carry out an evaluation of direct antiviral treatments against SARS-CoV-2 in these immunocompromised patients suffering from Covid-19.\n\nThe study consists of collecting patient care data from the medical record. Patients will be identified by practitioners at each participating French center.",[266,267],"Immunocompromised Patients","SARS-CoV-2 Disease",[269,270,271],"Immunocompromised patients","SARS-CoV-2 disease","Mono- or dual therapy with nirmatrelvir\u002Fritonavir or remdesivir","NOT_YET_RECRUITING","2025-09-05",{"date":275,"type":276},"2025-09-12","ACTUAL",{"date":278,"type":262},"2025-12-01",{"date":280,"type":262},"2026-06-01",{"name":5,"class":6},16]